Fedley Healthcare: India's Trusted Meropenem Injection 1gm IP Disodium EDTA

DCGI Approved WHO-GMP
RIVONEM 1GM by Fedley Healthcare
Injectables

RIVONEM 1GM

Product Composition

Meropenem Injection 1gm IP Disodium EDTA

Packing
1gm
Release Type
VIAL
DCGI Approved
WHO-GMP Certified
VIAL
Pan India Delivery
Get Franchise QuoteWhatsApp Us
ISO 9001:2015
1000+ Products
29+ States
Share:

Uses of RIVONEM 1GM

Meropenem Injection 1gm IP Disodium EDTA is prescribed for various conditions related to inflammation, pain, and joint disorders.

Quality-Driven Manufacturing Behind RIVONEM 1GM

1000+
DCGI Approved Products
12+
Years of Experience
2000+
Franchise Partners
29+
States Covered

PCD Pharma Franchise for Meropenem Injection 1gm IP Disodium EDTA — Available Across India

Fedley Healthcare provides exclusive monopoly-based PCD franchise rights for RIVONEM 1GM in all major states and union territories across India.

PunjabHaryanaRajasthanUttar PradeshMadhya PradeshGujaratMaharashtraKarnatakaTamil NaduKeralaAndhra PradeshTelanganaWest BengalBiharJharkhandOdishaChhattisgarhAssamMeghalayaTripuraManipurNagalandMizoramArunachal PradeshSikkimUttarakhandHimachal PradeshGoaJammu & KashmirDelhi NCRChandigarhPuducherry

Exclusive monopoly rights available — contact us to check availability in your state & district.

Why Fedley Healthcare vs Other Manufacturers?

See how we compare with typical pharma manufacturers in India.

Factor
Fedley Healthcare
Others
WHO-GMP Certification
Certified
Often Not
DCGI Approved Products
1000+
Limited
Monopoly Rights
Exclusive Territory
Shared
Marketing Support
Visual Aids, LBLs, Gifts
Minimal / Paid
Product Quality
SR Technology
Standard
Delivery
Pan India, On-Time
Delayed
MOQ (Min Order)
Flexible & Low
High Minimum
Profit Margins
Attractive (High ROI)
Thin Margins
Ethical Promotion
100% Ethical
Questionable
Franchise Support
Dedicated Manager
No Post-Sale Support
WHO-GMP Certification
Fedley
Certified
Others
Often Not
DCGI Approved Products
Fedley
1000+
Others
Limited
Monopoly Rights
Fedley
Exclusive Territory
Others
Shared
Marketing Support
Fedley
Visual Aids, LBLs, Gifts
Others
Minimal / Paid
Product Quality
Fedley
SR Technology
Others
Standard
Delivery
Fedley
Pan India, On-Time
Others
Delayed
MOQ (Min Order)
Fedley
Flexible & Low
Others
High Minimum
Profit Margins
Fedley
Attractive (High ROI)
Others
Thin Margins
Ethical Promotion
Fedley
100% Ethical
Others
Questionable
Franchise Support
Fedley
Dedicated Manager
Others
No Post-Sale Support

Start Your Pharma Business with RIVONEM 1GM — Get Exclusive Franchise Rights in Your State Today

Join 2000+ successful franchise partners across India. Low investment, high returns, complete marketing support.

Get Franchise Quote Now

Get Franchise Quote for RIVONEM 1GM

Interested in Meropenem Injection 1gm IP Disodium EDTA for your pharma franchise business? Fill the form and our team will get back to you with pricing, MOQ, and exclusive territory details.

  • Exclusive Monopoly Rights in Your Territory
  • Attractive Profit Margins & Low Investment
  • Timely Product Delivery Across India
  • Free Promotional Support (Visual Aids, LBLs, Gifts)

Send Enquiry

Fill in your details and we'll contact you shortly.

Product: RIVONEM 1GM | Meropenem Injection 1gm IP Disodium EDTA

Or call us: +91-9855986633 | +91-9317692852

Customer Reviews

4.7based on 87 ratings

RIVONEM 1GM has shown excellent results in my clinical practice. The Meropenem Injection 1gm IP Disodium EDTA formulation is well-balanced and patients report good tolerance with consistent therapeutic outcomes.

DR

Dr. Ramesh Kumar

Verified Purchase

12 Jun 2025

Excellent bioavailability with RIVONEM 1GM. The Meropenem Injection 1gm IP Disodium EDTA formulation is well-researched. Good product quality backed by proper DCGI documentation.

DA

Dr. Anil Mehta

Verified Purchase

14 Nov 2025

Highly recommend RIVONEM 1GM — the Meropenem Injection 1gm IP Disodium EDTA formulation is potent and well-manufactured. Timely delivery and proper documentation from Fedley Healthcare.

DK

Dr. Kavita Patel

Verified Purchase

22 Jan 2026